Laveta M Kid Tablet contains a combination of Levocetirizine (2.5 mg) and Montelukast (4 mg), formulated for pediatric use to manage allergic conditions. Levocetirizine is a non-sedating antihistamine that selectively inhibits peripheral H1 receptors, effectively reducing symptoms such as sneezing, nasal congestion, rhinorrhea, and itching associated with allergic rhinitis and chronic urticaria. Montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, thereby providing relief from asthma symptoms and improving respiratory function. The combination of these two agents offers a comprehensive approach to managing allergic rhinitis and asthma in children by addressing both histamine- and leukotriene-mediated pathways. Laveta M Kid Tablet is indicated for the treatment of seasonal and perennial allergic rhinitis, as well as for prophylaxis and chronic treatment of asthma in pediatric patients. It is generally well tolerated, with a low incidence of adverse effects such as headache, fatigue, and gastrointestinal discomfort. Dosage and administration should be as prescribed by a healthcare professional, considering the child’s age and clinical condition. This combination therapy enhances symptom control and improves quality of life in pediatric patients with allergic respiratory disorders.